Omnicell (OMCL) Total Debt (2016 - 2025)

Omnicell's (OMCL) quarterly Total Debt came in at $174.8 million in Q2 2025, little changed quarter-over-quarter from $174.6 million in Q1 2025.

Analysis

Omnicell (OMCL) Total Debt (2016 - 2025) Analysis & Trends

Omnicell (OMCL) has reported Total Debt for 8 consecutive years, with $174.8 million the latest figure, recorded in Q2 2025.

On a quarterly basis, Total Debt changed N/A year-over-year to $174.8 million in Q2 2025; TTM through Jun 2025 was $174.8 million, a N/A change from a year earlier, with the FY2024 full-year figure at $174.3 million, changed N/A from the prior year.
Total Debt was $174.8 million for Q2 2025 at Omnicell, roughly flat from $174.6 million in the prior quarter.
Over five years, Total Debt peaked at $572.0 million in Q3 2024 and troughed at $174.3 million in Q4 2024.
A 4-year average of $358.0 million and a median of $331.5 million in 2021 frame the typical range for Total Debt.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Abbott Laboratories	187.42 Bn	182.47 Bn	7.27 Bn	32.61 Bn
2	Intuitive Surgical	129.78 Bn	124.69 Bn	1.96 Bn	-
3	Medtronic	120.53 Bn	112.33 Bn	6.34 Bn	28.15 Bn
4	Stryker	116.28 Bn	112.80 Bn	4.50 Bn	14.94 Bn
5	Boston Scientific	69.29 Bn	68.99 Bn	3.85 Bn	12.62 Bn
6	Edwards Lifesciences	51.83 Bn	47.68 Bn	1.35 Bn	598.70 Mn
7	Alcon	34.36 Bn	32.91 Bn	1.68 Bn	4.15 Bn
8	Dexcom	33.17 Bn	31.23 Bn	830.00 Mn	-
9	Resmed	32.94 Bn	31.47 Bn	861.22 Mn	919.32 Mn
10	Omnicell	1.57 Bn	1.28 Bn	152.94 Mn	-

Historic Data

Download Data